Evidence for naltrexone monotherapy in obesity is limited and inconsistent
LIKELY EFFECTIVE Athletic/Physical performance Energy uses / Mitochondrial support Weight/fat loss Diabetes glucose and insulin sensitivity Diabetic neuropathy Cholesterol/lipid Nonalcoholic fatty liver disease (NAFLD) Cardiovascular support Hematologic oncologic/ Chemotherapy support Ophthalmic support Reproductive/fertility support Womens health PCOS Dermatologic support BENEFIT UNCLEAR/LIMITED EVIDENCE Diabetic nephropathy Diabetic retinopathy Immunity support/ antimicrobial properties Autoimmune conditions Neurologic support Musculoskeletal Burning Mouth Syndrome Neurovascular Migraine OTHER USES Endocrine ( insulin sensitivity ) Anti-aging ( antioxidant ), Neurotransmitter Support ( mental clarity, brain fog ) Immune Support ( liver detoxification, replenishes glutathione levels ), Energy ( mitochondria function), Metabolism ( weight loss ) Chelates mercury, arsenic and cadmium, Hepatitis Hepatitis C, HIV, Myopathy, Radiation damage, Vitiligo, Taste disorders, Prevention and treatment of mushroom poisoning ( amanita phalloides ), Burning mouth syndrome Possible Benefits Endocrine support : ALA mimics insulin, which both improves glucose metabolism and insulin sensitivity
One may gain weight when taken off Wegovy
This option should always be discussed with a qualified clinician
.webp)
